全文获取类型
收费全文 | 1681篇 |
免费 | 150篇 |
国内免费 | 47篇 |
专业分类
耳鼻咽喉 | 8篇 |
儿科学 | 80篇 |
妇产科学 | 36篇 |
基础医学 | 206篇 |
口腔科学 | 48篇 |
临床医学 | 239篇 |
内科学 | 433篇 |
皮肤病学 | 30篇 |
神经病学 | 105篇 |
特种医学 | 163篇 |
外科学 | 142篇 |
综合类 | 25篇 |
预防医学 | 90篇 |
眼科学 | 23篇 |
药学 | 79篇 |
1篇 | |
中国医学 | 9篇 |
肿瘤学 | 161篇 |
出版年
2022年 | 5篇 |
2021年 | 20篇 |
2020年 | 20篇 |
2019年 | 21篇 |
2018年 | 41篇 |
2017年 | 37篇 |
2016年 | 42篇 |
2015年 | 41篇 |
2014年 | 55篇 |
2013年 | 59篇 |
2012年 | 55篇 |
2011年 | 55篇 |
2010年 | 55篇 |
2009年 | 82篇 |
2008年 | 58篇 |
2007年 | 91篇 |
2006年 | 50篇 |
2005年 | 58篇 |
2004年 | 48篇 |
2003年 | 42篇 |
2002年 | 27篇 |
2001年 | 47篇 |
2000年 | 40篇 |
1999年 | 50篇 |
1998年 | 79篇 |
1997年 | 92篇 |
1996年 | 63篇 |
1995年 | 58篇 |
1994年 | 50篇 |
1993年 | 51篇 |
1992年 | 31篇 |
1991年 | 19篇 |
1990年 | 35篇 |
1989年 | 35篇 |
1988年 | 28篇 |
1987年 | 40篇 |
1986年 | 22篇 |
1985年 | 21篇 |
1984年 | 14篇 |
1983年 | 15篇 |
1982年 | 14篇 |
1981年 | 11篇 |
1980年 | 13篇 |
1979年 | 8篇 |
1978年 | 11篇 |
1977年 | 12篇 |
1976年 | 8篇 |
1975年 | 5篇 |
1974年 | 6篇 |
1972年 | 5篇 |
排序方式: 共有1878条查询结果,搜索用时 15 毫秒
91.
92.
Carlos O. Weiss MD Ravi Varadhan PhD Milo A. Puhan MD PhD Andrew Vickers PhD Karen Bandeen-Roche PhD MS Cynthia M. Boyd MD MPH David M. Kent MD CM MSc 《Journal of general internal medicine》2014,29(4):653-660
Most people with a chronic disease actually have more than one, a condition known as multimorbidity. Despite this, the evidence base to prevent adverse disease outcomes has taken a disease-specific approach. Drawing on a conference, Improving Guidelines for Multimorbid Patients, the goal of this paper is to identify challenges to the generation of evidence to support the care of people with multimorbidity and to make recommendations for improvement. We identified three broad categories of challenges: 1) challenges to defining and measuring multimorbidity; 2) challenges related to the effects of multimorbidity on study design, implementation and analysis; and 3) challenges inherent in studying heterogeneity of treatment effects in patients with differing comorbid conditions. We propose a set of recommendations for consideration by investigators and others (reviewers, editors, funding agencies, policymaking organizations) involved in the creation of evidence for this common type of person that address each of these challenges. The recommendations reflect a general approach that emphasizes broader inclusion (recruitment and retention) of patients with multimorbidity, coupled with more rigorous efforts to measure comorbidity and comorbidity burden and the influence of multimorbidity on outcomes and the effects of therapy. More rigorous examination of heterogeneity of treatment effects requires careful attention to prioritizing the most important comorbid-related questions, and also requires studies that provide greater statistical power than conventional trials have provided. Relatively modest changes in the orientation of current research along these lines can be helpful in pointing to and partially addressing selected knowledge gaps. However, producing a robust evidence base to support patient-centered decision making in complex individuals with multimorbidity, exposed to many different combinations of potentially interacting factors that can modify the risks and benefits of therapies, is likely to require a clinical research enterprise fundamentally restructured to be more fully integrated with routine clinical practice. 相似文献
93.
Hematopoietic chimerism can be used as a tool for patient management after allogeneic hematopoietic stem cell transplantation (HSCT). An increase in the proportion of recipient cells after transplantation is strongly associated with relapse in chronic myeloid leukemia. However, in acute myeloid leukemia (AML) the significance of increasing mixed chimerism (MC) as a predictive marker for relapse is less clear. Several mutations frequently found in AML have been employed for minimal residual disease detection and relapse prediction. Therefore, a combined analysis of hematopoietic chimerism and of the molecular aberrations found in AML could be used to improve MC characterization. We developed a multiplex PCR for use in the simultaneous detection of hematopoietic chimerism and mutations in nucleophosmin (NPM1) and fms-like tyrosine kinase-3 internal tandem duplication (FLT3-ITD). A total of 303 samples from 20 AML patients were analyzed after HSCT. The microsatellite markers used for hematopoietic chimerism detection were D1S80, D7S1517, D4S2366, THO1, and SE33. A total of 149 samples from 18 patients showed MC with a mean detection time of 9.7 months. From the 18 patients with MC, in 6 of the patients, no FLT3-ITD or NPM1 mutation was found at any time point tested, and these patients remained in complete hematological remission. In 12 patients with MC, FLT3-ITD and NPM1 mutations were found, and these patients showed signs of hematological relapse. Our combined analysis of NPM1/FLT3-ITD mutations and hematopoietic chimerism improved the characterization of patients with MC after HSCT. The present approach may be further expanded by combining additional mutations found in AML with hematopoietic chimerism detection. 相似文献
94.
95.
Anna Wirthmann Juliane C. Finke Pietro Giovanoli Nicole Lindenblatt 《European journal of plastic surgery》2014,37(3):159-166
Background
The radial forearm flap (RFF) is known for its excellent and reliable results regarding defect coverage though donor site morbidity represents a persisting problem. Integra is widely used in reconstructive surgery. This study aims to assess long-term outcomes regarding functionality and cosmesis after donor site coverage with respect to esthetic appearance, scar quality, and wrist function as well as ability to work after donor site coverage with Integra and split-thickness skin.Methods
The prospective follow-up exam, after a mean time of 23.8 months, enrolled 13 patients. Identification of patients’ comorbidities and evaluation of the subjective esthetic outcome, sensibility, cold intolerance, and scar instability was assessed by a questionnaire. In clinics, designed Pinch test assessed scar tissue mobility over the flexor tendons. The Vancouver Scar Scale (VSS) was calculated; wrist function and grip strength were determined.Results
The satisfaction score for the esthetic appearance of the donor site was in average 3.42?±?0.44. Two patients experienced an unstable scar and cold intolerance. The VSS resulted in a value of 4.2 representing a good result. The pinch test revealed an average scar mobility of 8 mm without any tendon adhesions. Active range of motion of the wrist was equal to the non-operated site as was grip strength. The pinch test showed a significant negative correlation with the VSS making it a reliable tool to measure scar quality.Conclusion
Long-term results show an esthetic and functional successful defect coverage of the RFF donor site by the use of Integra and split-thickness skin. Level of Evidence: Level IV, therapeutic study. 相似文献96.
Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease 总被引:7,自引:0,他引:7 下载免费PDF全文
Binks M Passweg JR Furst D McSweeney P Sullivan K Besenthal C Finke J Peter HH van Laar J Breedveld FC Fibbe WE Farge D Gluckman E Locatelli F Martini A van den Hoogen F van de Putte L Schattenberg AV Arnold R Bacon PA Emery P Espigado I Hertenstein B Hiepe F Kashyap A Kötter I Marmont A Martinez A Pascual MJ Gratwohl A Prentice HG Black C Tyndall A 《Annals of the rheumatic diseases》2001,60(6):577-584
BACKGROUND: Systemic sclerosis (SSc, scleroderma) in either its diffuse or limited skin forms has a high mortality when vital organs are affected. No treatment has been shown to influence the outcome or significantly affect the skin score, though many forms of immunosuppression have been tried. Recent developments in haemopoietic stem cell transplantation (HSCT) have allowed the application of profound immunosuppression followed by HSCT, or rescue, to autoimmune diseases such as SSc. METHODS: Results for 41 patients included in continuing multicentre open phase I/II studies using HSCT in the treatment of poor prognosis SSc are reported. Thirty seven patients had a predominantly diffuse skin form of the disease and four the limited form, with some clinical overlap. Median age was 41 years with a 5:1 female to male ratio. The skin score was >50% of maximum in 20/33 (61%) patients, with some lung disease attributable to SSc in 28/37 (76%), the forced vital capacity being <70% of the predicted value in 18/36 (50%). Pulmonary hypertension was described in 7/37 (19%) patients and renal disease in 5/37 (14%). The Scl-70 antibody was positive in 18/32 (56%) and the anticentromere antibody in 10% of evaluable patients. Peripheral blood stem cell mobilisation was performed with cyclophosphamide or granulocyte colony stimulating factor, alone or in combination. Thirty eight patients had ex vivo CD34 stem cell selection, with additional T cell depletion in seven. Seven conditioning regimens were used, but six of these used haemoimmunoablative doses of cyclophosphamide +/- anti-thymocyte globulin +/- total body irradiation. The median duration of follow up was 12 months (3-55). RESULTS: An improvement in skin score of >25% after transplantation occurred in 20/29 (69%) evaluable patients, and deterioration in 2/29 (7%). Lung function did not change significantly after transplantation. One of five renal cases deteriorated but with no new occurrences of renal disease after HSCT, and the pulmonary hypertension did not progress in the evaluable cases. Disease progression was seen in 7/37 (19%) patients after HSCT with a median period of 67 (range 49-255) days. Eleven (27%) patients had died at census and seven (17%) deaths were considered to be related to the procedure (direct organ toxicity in four, haemorrhage in two, and infection/neutropenic fever in one). The cumulative probability of survival at one year was 73% (95% CI 58 to 88) by Kaplan-Meier analysis. CONCLUSION: Despite a higher procedure related mortality rate from HSCT in SSc compared with patients with breast cancer and non-Hodgkin's lymphoma, the marked impact on skin score, a surrogate marker of mortality, the trend towards stabilisation of lung involvement, and lack of other treatment alternatives justify further carefully designed studies. If future trials incorporate inclusion and exclusion criteria based on this preliminary experience, the predicted procedure related mortality should be around 10%. 相似文献
97.
Robert Zeiser Dietrich W. Beelen Wolfgang Bethge Martin Bornhäuser Gesine Bug Andreas Burchert Maximilian Christopeit Justus Duyster Jürgen Finke Armin Gerbitz Jan Henning Klusmann Guido Kobbe Michael Lübbert Carsten Müller-Tidow Uwe Platzbecker Wolf Rösler Martin Sauer Christoph Schmid Lutz P. Müller 《Biology of blood and marrow transplantation》2019,25(4):e128-e140
The curative potential of allogeneic hematopoietic cell transplantation (allo-HCT) in the treatment of acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) relies mainly on the graft-versus-leukemia effect. Relapse after allo-HCT occurs in a considerable proportion of patients and has a dismal prognosis, with still very limited curative potential. This review provides an overview of the established and evolving approaches to preventing or treating relapse of AML and MDS after allo-HCT, in the context of novel insight into the biology of relapse. Established prophylactic measures to prevent relapse include optimized conditioning and graft-versus-host disease (GVHD) prophylaxis, as well as donor lymphocyte infusion (DLI) for high-risk patients; novel immunomodulatory interventions and maintenance approaches are still experimental. Improved diagnostics can detect persistent or recurring disease at a molecular level, enabling early preemptive interventions. Established options include hypomethylating agents and DLI. Standard treatments for hematologic relapse include chemotherapy, cessation of immunosuppressive treatment, and DLI. Experimental approaches include molecular targeted therapies, novel immunomodulatory treatments, and second allo-HCT. For all interventions, the potential risks, including occurrence of GVHD, must be weighed against the benefits individually in each patient. Concurrently, prevention and treatment of relapse after allo-HCT remain challenging and unmet medical needs. 相似文献
98.
99.
100.